MedTrace Logo

Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis

NCT02258867 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2015-12-29

No results posted yet for this study

Summary

The objective of this study is to assess the efficacy and safety of gevokizumab in treating Behcet's disease uveitis (BDU).

Conditions

  • Behcet's Disease Uveitis

Interventions

DRUG

Placebo

Solution for subcutaneous injection

DRUG

Gevokizumab

Solution for subcutaneous injection

Sponsors & Collaborators

  • XOMA (US) LLC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2015-10-31
Completion
2015-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02258867 on ClinicalTrials.gov